Mutations which activate the members of the family can be found in as much as 20–30% of all human tumours, and mutations in the KRAS isoform can be found in 95% of pancreatic ductal adenocarcinoma and the vast majority of colon and lung tumours [22]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.